Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 18/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 18/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 16/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5837782 | 0.99 | HTR2A (0.56) | HTR2ASLC6A4CYP3A4TSHRKCNH2 | |
| SCHEMBL6740272 | 0.82 | HTR2A (0.47) | HTR2ASLC6A4KCNH2HSP90AA1SLC6A2 | |
| SCHEMBL11460671 | 0.79 | HTR2A (0.63) | HTR2ASLC6A4CYP3A4TSHRKCNH2 | |
| SCHEMBL13857896 | 0.77 | HTR2A (0.61) | HTR2ASLC6A4CYP3A4TSHRKCNH2 | |
| SCHEMBL22069600 | 0.75 | HTR2A (0.58) | HTR2ASLC6A4CYP3A4TSHRKCNH2 | |
| SCHEMBL5837285 | 0.72 | SLC6A4 (1.00) | HTR2ASLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL27536429 | 0.72 | ALDH1A1 (0.47) | CYP3A4TSHR | |
| SCHEMBL28288101 | 0.72 | HTR2A (0.55) | HTR2ASLC6A4CYP3A4TSHRKCNH2 | |
| SCHEMBL632533 | 0.71 | MAOA (0.61) | HTR2ASLC6A4CYP3A4TSHRHSP90AA1 | |
| SCHEMBL31287824 | 0.71 | MAOA (0.61) | HTR2ASLC6A4CYP3A4TSHRHSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7084165-B2 | Monoamine reuptake inhibitors for treatment of CNS disorders | PFIZER INC (US) | 2006-08-01 | — | — | US | disclosed |
| US-20040048856-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | PFIZER INC | 2004-03-11 | — | — | US | disclosed |
| US-20020143003-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | PFIZER INC. | 2002-10-03 | — | — | US | disclosed |
| EP-1154984-A1 | INHIBITORS FOR UPTAKE OF SEROTONINE, DOPAMINE OR NOREPINEPHRINE | Pfizer Products Inc. (US) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050380-A1 | MONOAMINE REUPTAKE INHIBITORS FOR TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143003-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | SLC6A2, SLC6A4, SLC6A3 | HTR2A 24/4885SLC6A4 2/4885CYP3A4 290/4885 |
| US-20040048856-A1 | Monoamine reuptake inhibitors for treatment of CNS disorders | SLC6A2, SLC6A3, SLC18A2 | HTR2A 14/4885SLC6A4 4/4885CYP3A4 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.